Acorda Therapeutics, Inc. (ACOR)
(Delayed Data from NSDQ)
$11.74 USD
+1.16 (10.96%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.74 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.74 USD
+1.16 (10.96%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.74 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Vertex's Orkambi Wins EU Nod to Treat Cystic Fibrosis in Kids
by Zacks Equity Research
Vertex (VRTX) gains an EU approval for Orkambi to treat 2-5-year-old children suffering cystic fibrosis (CF).
Aerpio (ARPO) Jumps: Stock Rises 7.8%
by Zacks Equity Research
Aerpio (ARPO) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Nabriva Therapeutics (NBRV) Jumps: Stock Rises 6.7%
by Zacks Equity Research
Nabriva Therapeutics (NBRV) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study
by Zacks Equity Research
ASLAN's (ASLN) varlitinib is unable to show any statistical significance for the primary endpoint in a phase II study with regard to first-line treatment of advanced or metastatic gastric cancer.
Apellis Pharmaceuticals (APLS) in Focus: Stock Moves 7.1% Higher
by Zacks Equity Research
Apellis Pharmaceuticals (APLS) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Acorda (ACOR) Plans to Launch Inbrija in Q1: What to Expect
by Zacks Equity Research
Acorda (ACOR) aims to unveil its newly FDA-approved Parkinson's disease drug, Inbrija, in the first quarter of 2019. The company's pipeline looks strong.
Mirati Therapeutics (MRTX) Catches Eye: Stock Jumps 5.4%
by Zacks Equity Research
Mirati Therapeutics (MRTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Myriad Genetics (MYGN) Catches Eye: Stock Jumps 6.9%
by Zacks Equity Research
Myriad Genetics (MYGN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Company News For Dec 26, 2018
by Zacks Equity Research
Companies In The News Are: AAPL,MB,TSLA,ACOR
Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal
by Zacks Equity Research
It was a busy week for the biotech sector with quite a few FDA approvals and some strategic partnerships.
Acorda Gets FDA Approval for Parkinson's Disease Drug Inbrija
by Zacks Equity Research
Acorda (ACOR) gains an FDA nod for its lead Parkinson's drug Inbrija pertaining to the treatment of OFF periods in patients afflicted with the disease.
Acorda (ACOR) Down 0.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Acorda (ACOR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Acorda Down More Than 30% in the Past 3 Months: Here's Why
by Zacks Equity Research
Acorda's (ACOR) lead MS drug Ampyra is hit by generic competition in the United States while its lead Parkinson disease candidate Inbrija's review timeline gets extended by three months.
Acorda (ACOR) Q3 Earnings Top Estimates, Ampyra Sales View Up
by Zacks Equity Research
Acorda's (ACOR) Q3 rides high on earnings and revenue beat amid a strong generic competition for its MS drug Ampyra and the expected launch of its Parkinson's candidate, Inbrija.
Acorda Therapeutics (ACOR) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Acorda (ACOR) delivered earnings and revenue surprises of 13.33% and 68.52%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Acorda Therapeutics (ACOR) Q3 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
Acorda (ACOR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Centene's (CNC) Earnings and Revenues Top Estimates in Q3
by Zacks Equity Research
Execution of growth strategy as well as the company's solid operating metrics leads Centene (CNC) to an earnings beat in Q3.
Acorda (ACOR) Stock Dips, FDA Delays Decision on Inbrija
by Zacks Equity Research
The FDA defers decision by three months regarding the NDA of Acorda's (ACOR) Parkinson's disease candidate Inbrija for the treatment of OFF periods.
Acorda Gets Unfavorable Court Ruling for Ampyra, Stock Down
by Zacks Equity Research
Acorda Therapeutics' (ACOR) stock slumps after a Federal Circuit Court rules against its appeal to protect patents pertaining to its key multiple sclerosis drug, Ampyra
Are Options Traders Betting on a Big Move in Acorda (ACOR) Stock?
by Zacks Equity Research
Investors need to pay close attention to Acorda (ACOR) stock based on the movements in the options market lately.
Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Acorda Therapeutics (ACOR) rides high on earnings as well as revenue beat in Q2.
Is the Options Market Predicting a Spike in Acorda Therapeutics (ACOR) Stock?
by Zacks Equity Research
Investors need to pay close attention to Acorda Therapeutics (ACOR) stock based on the movements in the options market lately.
Acorda Therapeutics (ACOR) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Acorda (ACOR) delivered earnings and revenue surprises of 86.67% and 19.10%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Cardinal Health (CAH) in Q4 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) is likely to witness solid growth in the core Pharmaceutical segment in Q4 results. However, lackluster performance in the Cordis unit is likely to mar prospects.
Is a Beat in Store for Vertex (VRTX) This Earnings Season?
by Zacks Equity Research
Vertex Pharma (VRTX) is expected to beat estimates when it reports second-quarter earnings on Jul 25.